sGC 1061, a unique CNS active nitric oxide mimetic agent, has been shown in a series of preclinical studies to improve neurocognitive function in animal models. sGC 1061 has shown effects on cognition and memory, as well as neuron survival in ex vivo and in vivo experimental animal studies, and has therefore been recently selected for clinical development in the Alzheimer's Disease/cognitive impairment indication. sGC 1061 has been promoted into clinical development and has undergone a phase 1 clinical trial with an immediate release aqueous formulation. The results of this study indicate suitable bioavailability, with plasma concentrations that are in a general range that has been associated with neuropharmacological benefits in preclinical studies in rodent models. This program is directed at the development of a sustained release form of this drug tht will allow twice daily dosing in humans.